Vivoryon Therapeutics N.V. (05Y.F)

Compare

1.7460

+0.0160

+(0.92%)

At close: April 4 at 12:15:49 PM GMT+2

Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. last month

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Halle (Saale) / Munich, Germany, February 19, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual R&D update with KOL (Key Opinion Leader) speakers held February 1

GlobeNewswire last month

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025

Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025 Halle (Saale) / Munich, Germany, February 11, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced to host a virtual R&D update with KOL (Key Opinion Leader) speakers on February 18, 2025.

GlobeNewswire last month

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

Figure_1_2025-01-14_VVY Figure 1: Difference of change from baseline between varoglutamstat (v) and placebo (p) of eGFR (MDRD) - All Subjects Figure_2_2025-01-14_VVY Figure 2: Difference of change from baseline between varoglutamstat (v) and placebo (p) of eGFR (MDRD) - Diabetes / No Diabetes Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease A meta-analysis of VIVIAD and VIVA-MIND1 data confirmed that treatment with varoglutamstat at 600m

GlobeNewswire 2 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and ...

Vivoryon Therapeutics NV (STU:05Y) reports promising kidney study results amid financial constraints and strategic pivots.

GuruFocus.com 3 months ago

VVY.AS
-4.89%
New strategy for Vivoryon as second failed Alzheimer’s trial shows kidney promise

Vivoryon's VIVA-MIND trial echoed the disappointing Alzheimer’s findings of its VIVIAD trial but offers promise in treating kidney function.

Clinical Trials Arena 3 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease Varoglutamstat Phase 2 program shows highly consistent, statistically significant and clinically meaningful improvement of kidney function (eGFR1) versus placebo in two independent randomized double-blind placebo-controlled studiesVIVA-MIND topline analysis of kidney function data reported yesterday provides a second Phase 2 long-term dataset demonstrating varoglutamstat’s potential to

GlobeNewswire 3 months ago

VVY.AS
-4.89%
Promising Penny Stocks To Consider In December 2024

As global markets continue to experience mixed performances, with major U.S. indexes reaching record highs while smaller-cap stocks face declines, investors are keenly observing economic indicators and central bank policies for future direction. In this context, the allure of penny stocks remains significant despite their somewhat outdated terminology. These stocks often represent smaller or newer companies that can offer both affordability and growth potential when backed by strong financials.

Simply Wall St. 3 months ago

VVY.AS
-4.89%
2517.HK

UPP.AE
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data fromVIVA-MIND Strongly Supporting Varoglutamstat’s Potential toImprove Kidney Function VIVA-MIND Phase 2 data confirm results of varoglutamstat’s benefit on eGFR in VIVIAD; Company now has two independent double-blind placebo-controlled Phase 2 studies demonstrating a clinically meaningful treatment effect on kidney functionTopline analysis of kidney function data in VIVA-MIND shows a statistically significant and clinically meaningful imp

GlobeNewswire 3 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Halle (Saale) / Munich, Germany, December 04, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its third quarter financial results for the period en

GlobeNewswire 3 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Selected for late-breaking oral presentation at ASN kidney week, the world’s premier nephrology meetingResults presented show a statistically significant and clinically meaningful improvement of the prospectively defined kidney function parameter eGFR1 by 3.4mL/min/year (p<0.0001) in the varoglutamstat arm compared to placebo Results in the subgroup of patients with diabe

GlobeNewswire 5 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s abstract “Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kid

GlobeNewswire 5 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual Kidney Disease Key Opinion Leader (KOL) Event held September 30, 2024. The event focused on the standard of care and existing medical need, market develop

GlobeNewswire 6 months ago

VVY.AS
-4.89%
This Vivoryon Therapeutics Insider Increased Their Holding By 143% Last Year

Looking at Vivoryon Therapeutics N.V.'s ( AMS:VVY ) insider transactions over the last year, we can see that insiders...

Simply Wall St. 6 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Primary focus is developing varoglutamstat, a Phase 2 investigational medicine with potential to improve kidney function in patients with kidney diseaseStatistically significant benefit of varoglutamstat on prospectively defined key kidney function endpoint (eGFR1) and significant reduction of pro-inflammatory cytokine pE-CCL2 observe

GlobeNewswire 6 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Halle (Saale) / Munich, Germany, September 5, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it has completed the reduction of its share capit

GlobeNewswire 6 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Halle (Saale) / Munich, Germany, September 5, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will host two events in September: Half year

GlobeNewswire 6 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease New data confirm beneficial treatment effect of varoglutamstat on kidney functionTreatment effect1 in diabetes subgroup2 of >8mL/min/1.73m2/year in estimated glomerular filtration rate (eGFR); reinforces previously reported treatment effect of 3.4mL/min/1.73m2/year (p<0.001) in the

GlobeNewswire 8 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Halle (Saale) / Munich, Germany, July 9, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will host an R&D update conference call and webcast on Thursday, July 18,

GlobeNewswire 8 months ago

VVY.AS
-4.89%
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Halle (Saale) / Munich, Germany, June 21, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, held its Annual General Meeting (AGM) today at 1:00 p.m. (CEST). The shareholders approved all items on the agend

GlobeNewswire 9 months ago

VVY.AS
-4.89%

Performance Overview

Return	05Y.F	AEX-Index (^AEX)
YTD	-12.00%	-4.25%
1-Year	+233.21%	-4.85%
3-Year	-83.95%	+14.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vivoryon Therapeutics N.V. (05Y.F)

Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025

Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and ...

New strategy for Vivoryon as second failed Alzheimer’s trial shows kidney promise

Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease

Promising Penny Stocks To Consider In December 2024

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

This Vivoryon Therapeutics Insider Increased Their Holding By 143% Last Year

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting

Performance Overview